Medication info
Cozaar Plus Pro Tablet

Cozaar Plus Pro Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Organon Korea Co., Ltd.
Appearance
An oval film-coated tablet ranging from white to grayish-white with “745” engraved on one side.
Packaging
30 tablets (10 tablets/PTP x 3 PTP), 100 tablets (100 tablets/bottle)
Approval status
Active

MFDS item code 200807526 · Notified 2008.07.07 · Insurance code 073100360

Summary

Main use
Treatment of hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect is achieved approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, treatment with this medicine should be initiated when the expected effect is not achieved with monotherapy. 1. Replacement therapy : A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy : Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy : Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose : Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. The clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should then be monitored continuously; if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Use of a loop diuretic rather than a thiazide drug is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment Because the initial losartan potassium dose of 25 mg required for patients with hepatic impairment who need dose adjustment cannot be administered with this medicine, use in these patients is not recommended.
Child dose
Under 18 years: There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Importer
Organon Korea Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled by monotherapy

  • Hypertension
View approved original text

This medication is used to effectively lower and control blood pressure in patients with hypertension where adequate control is not achieved by monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect is achieved approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, treatment with this medicine should be initiated when the expected effect is not achieved with monotherapy. 1. Replacement therapy : A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy : Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy : Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose : Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. The clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should then be monitored continuously; if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Use of a loop diuretic rather than a thiazide drug is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment Because the initial losartan potassium dose of 25 mg required for patients with hepatic impairment who need dose adjustment cannot be administered with this medicine, use in these patients is not recommended.

Child dose

Under 18 years: There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can pose a serious risk to the fetus and newborn during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Pregnant women or those who may become pregnant should not use this medication as it can affect the development of the fetus's lungs or skeleton. This medication should not be administered to patients with certain conditions, such as anuria, severe hepatic or renal impairment, hyperuricemia, or severe electrolyte disturbances. Additionally, those with hypersensitivity to this medication or allergies to sulfonamide drugs should avoid its use. Patients with hypotension, impaired kidney function, liver disease, cerebrovascular disease, or diabetes should use this medication cautiously and have their condition regularly monitored while on treatment. The hydrochlorothiazide component may cause electrolyte imbalances, so electrolyte levels should be regularly checked through blood tests. This medication can lower blood pressure, so dizziness or drowsiness may occur at the beginning of treatment or when adjusting the dose; caution is advised when driving or operating machinery. There may be interactions with other medications, so special care should be taken to avoid concurrent use with potassium supplements or potassium-sparing diuretics. It is advisable to avoid grapefruit juice while taking this medication, and exposure to sunlight should be limited since the risk of skin cancer may increase; skin condition should be periodically monitored. This medication has not been studied in children and adolescents, so it should not be administered to them. Elderly patients may experience adverse reactions more frequently, hence caution is required. If any unusual symptoms occur during treatment, consult a healthcare professional immediately, and discuss with a doctor if pregnant or planning to become pregnant. Finally, this medication should be stored out of reach of children and securely stored in its original container.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • low back pain
  • dizziness
Show 130 more
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
  • skin desquamation
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary AV block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle stiffness
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • nerve hypersensitivity
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremor
  • dizziness
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disturbance
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitive reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • eye pain
  • burning sensation
  • conjunctivitis
  • vision loss
  • taste disturbances
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • seizures
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • hemolytic anemia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle twitching
  • restlessness
  • renal failure
  • renal impairment
  • interstitial nephritis
  • mucous membrane syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal effusion
  • vasculitis
  • anaphylaxis
  • hepatitis
  • dry cough
  • erythema
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a light-resistant container due to sensitivity to light. Additionally, it should be kept at room temperature between 1°C and 30°C. Storing in this manner will help maintain the medication's efficacy and safety.

Appearance and packaging

Appearance

An oval film-coated tablet ranging from white to grayish-white with “745” engraved on one side.

Package unit

30 tablets (10 tablets/PTP x 3 PTP), 100 tablets (100 tablets/bottle)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.